Piper Jaffray Starts TELA Bio, Inc. (TELA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
JMP Securities Starts TELA Bio, Inc. (TELA) at Market Outperform
December 3, 2019 7:47 AM ESTJMP Securities analyst David Turklay initiates coverage on TELA Bio, Inc. (NASDAQ: TELA) with a Market Outperform rating and a price target of $22.00.
The analyst comments "Rarely does one see new medical solutions that provide significant benefits to essentially all constituents (i.e.,... More
Canaccord Genuity Starts TELA Bio, Inc. (TELA) at Buy
December 3, 2019 5:17 AM ESTCanaccord Genuity analyst Kyle Rose initiates coverage on TELA Bio, Inc. (NASDAQ: TELA) with a Buy rating and a price target of $19.00.
For an analyst ratings summary and ratings history on TELA Bio, Inc.... More
